Fundz
New|Fundz now works inside Claude2 min

Timing. Relevance. Relationships.

Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.

Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

Vivos Therapeutics Acquires SOD Sciences in Strategic Asset Exchange

PRIVATEOct 15, 2026

Acquiring Company

Vivos Therapeutics

Acquired Company

SOD Sciences

DelawareFloridaBiotechnologyHealth CareTherapeuticsBiotechnologyHealth Care

Description

On October 14, 2026, Vivos Therapeutics, Inc. entered into a Mutual Stock Purchase and Asset Exchange Agreement with SOD Sciences, Inc. As part of the agreement, Vivos will issue 12,000 shares of a new series of preferred stock in exchange for SOD common stock and co-ownership of a patented early-warning test. The closing of the transaction is expected on October 15, 2026.

Company Information

Company

Vivos Therapeutics

Location

Delaware, United States

About

Vivos Therapeutics, Inc. is a Delaware corporation focused on innovative technologies for treating breathing disorders. The company specializes in developing solutions for sleep-disordered breathing and related conditions. Vivos aims to improve patient outcomes through its unique approaches and products.

Fundz sees it the moment Vivos Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Vivos Therapeutics's next move

Learn about Strategic plan

Frequently asked

Who acquired SOD Sciences?

SOD Sciences was acquired by Vivos Therapeutics, based in Delaware. The deal was reported on October 15, 2026. Vivos Therapeutics, Inc. is a Delaware corporation focused on innovative technologies for treating breathing disorders. Vivos Therapeutics is privately held and operates in Biotechnology.

When did Vivos Therapeutics acquire SOD Sciences?

Vivos Therapeutics's acquisition of SOD Sciences was reported on October 15, 2026. On October 14, 2026, Vivos Therapeutics, Inc. entered into a Mutual Stock Purchase and Asset Exchange Agreement with SOD Sciences, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does SOD Sciences do?

SOD Sciences, Inc. is a Florida corporation that specializes in innovative health testing and treatment protocols. The company is known for its ReBalU Protocol, a test/treat/retest platform that includes patent filings for a pseudohypoxia early-warning test. It is privately held, operating in Biotechnology, and is based in Florida.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.